{
    "clinical_study": {
        "@rank": "2997", 
        "arm_group": [
            {
                "arm_group_label": "Tabalumab Auto-Injector", 
                "arm_group_type": "Experimental", 
                "description": "Tabalumab given Week 0 as a loading dose of 180 milligram (mg) given as two subcutaneous (SC) injections each of 90 mg followed by 90 mg SC injections every two weeks."
            }, 
            {
                "arm_group_label": "Tabalumab Prefilled Syringe", 
                "arm_group_type": "Experimental", 
                "description": "Tabalumab given Week 0 as a loading dose of 180 mg given as two SC injections each of 90 mg followed by 90 mg SC injections every two weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the serum concentration of tabalumab after the\n      administration using either prefilled syringe or auto-injector after the initial loading\n      dose and after 12 weeks of treatment. Treatment period is followed by 40 weeks optional\n      safety extension."
        }, 
        "brief_title": "Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA)", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ambulatory males or females \u226518 years of age\n\n          -  Diagnosis of adult-onset RA\n\n          -  Active RA (at least 8/68 tender and at least 8/66 swollen joints)\n\n          -  Screening C-reactive protein >1.2 times the upper limit of normal (ULN) or a\n             screening erythrocyte sedimentation rate (ESR) >28 millimeters per hour (mm/hr)\n\n          -  Documented history of, or current, positive rheumatoid factor (RF) and/or anti-cyclic\n             citrullinated peptide antibody (anti-CCP Ab) test\n\n          -  Regular use of methotrexate (MTX) for at least 12 weeks and stable dose (10 to 25\n             mg/week) for at least 8 weeks prior to baseline\n\n          -  American College of Rheumatology (ACR) functional class I, II, or III\n\n          -  Able and willing to inject tabalumab by themselves (or have an assistant who will\n             inject tabalumab) and able and willing to complete all study procedures\n\n          -  Able and willing to have blood drawn for pharmacokinetic (PK) sampling\n\n        Exclusion Criteria:\n\n          -  Use of oral corticosteroids at average daily doses of >10 mg/day of prednisone or its\n             equivalent within 6 weeks prior to baseline\n\n          -  Injection of any parenteral (including intraarticular) corticosteroid within 6 weeks\n             of baseline\n\n          -  Have previously discontinued treatment with a biologic disease-modifying\n             antirheumatic drug (DMARD) or a novel drug that interrupts cytokine signaling (eg,\n             Janus kinase [JAK] inhibitors) due to insufficient efficacy\n\n          -  Participants who had discontinued biologic DMARDS for reasons other than efficacy\n             will not be excluded but must have done so prior to baseline\n\n          -  Participants who discontinued a JAK inhibitor for lack of efficacy\n\n          -  Participants who discontinued a JAK inhibitor for reasons other than efficacy will\n             not be excluded, but must have done so prior to baseline for 21 days\n\n          -  Previous severe reaction to any biologic therapy that, in the opinion of the\n             Investigator, would pose an unacceptable risk to the participant if participating in\n             the study\n\n          -  Have had an inadequate response to treatment with 3 or more of the following DMARDs\n             prescribed alone or in combination at approved doses for a minimum of 90 days:\n             leflunomide, azathioprine, cyclosporine, and/or sulfasalazine\n\n          -  Use of other DMARDs (eg, gold salts, cyclosporin, azathioprine, or any other\n             immunosuppressives) other than MTX, hydroxychloroquine, chloroquine, or\n             sulfasalazine, or the use of a JAK inhibitor in the 8 weeks prior to baseline"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01676701", 
            "org_study_id": "14598", 
            "secondary_id": "H9B-MC-BCEF"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tabalumab Auto-Injector", 
                "description": "Administered SC by auto-injector", 
                "intervention_name": "Tabalumab Auto-Injector", 
                "intervention_type": "Drug", 
                "other_name": "LY2127399"
            }, 
            {
                "arm_group_label": "Tabalumab Prefilled Syringe", 
                "description": "Administered SC by prefilled syringe", 
                "intervention_name": "Tabalumab Prefilled Syringe", 
                "intervention_type": "Drug", 
                "other_name": "LY2127399"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Glendale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85304"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lewes", 
                        "country": "United States", 
                        "state": "Delaware", 
                        "zip": "19958"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Debary", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32713"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tamarac", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33321"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46260"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prairie Village", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66206"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lansing", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48910"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Springfield", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "68507"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63141"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Las Vegas", 
                        "country": "United States", 
                        "state": "Nevada", 
                        "zip": "89128"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Freehold", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07728"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19152"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wyomissing", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19610"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spokane", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "99204"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buenos Aires", 
                        "country": "Argentina", 
                        "zip": "C1015ABO"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "C\u00f3rdoba", 
                        "country": "Argentina", 
                        "zip": "5000"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quilmes", 
                        "country": "Argentina", 
                        "zip": "B1878DVC"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Juan", 
                        "country": "Argentina", 
                        "zip": "5400"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tucuman", 
                        "country": "Argentina", 
                        "zip": "4000"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hostivice", 
                        "country": "Czech Republic", 
                        "zip": "253-01"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Plzen-Bory", 
                        "country": "Czech Republic", 
                        "zip": "305 99"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prague", 
                        "country": "Czech Republic", 
                        "zip": "140 59"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Uherske Hradiste", 
                        "country": "Czech Republic", 
                        "zip": "686 01"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zlin", 
                        "country": "Czech Republic", 
                        "zip": "760 01"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bialystok", 
                        "country": "Poland", 
                        "zip": "15-351"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bydgoszcz", 
                        "country": "Poland", 
                        "zip": "85-168"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Elblag", 
                        "country": "Poland", 
                        "zip": "82300"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lublin", 
                        "country": "Poland", 
                        "zip": "20-607"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Poznan", 
                        "country": "Poland", 
                        "zip": "60-218"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ponce", 
                        "country": "Puerto Rico", 
                        "zip": "00716"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Juan", 
                        "country": "Puerto Rico", 
                        "zip": "00918"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santurce", 
                        "country": "Puerto Rico", 
                        "zip": "00909"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "119435"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "194291"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saratov", 
                        "country": "Russian Federation", 
                        "zip": "410026"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ulyanovsk", 
                        "country": "Russian Federation", 
                        "zip": "432063"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yaroslavl", 
                        "country": "Russian Federation", 
                        "zip": "150003"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Argentina", 
                "Czech Republic", 
                "Poland", 
                "Puerto Rico", 
                "Russian Federation"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled Syringe or Auto Injector in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
                "Czech Republic: State Institute for Drug Control", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Russia: Ministry of Health of the Russian Federation"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics (PK): Maximum serum concentration (Cmax) of tabalumab after loading dose", 
                "safety_issue": "No", 
                "time_frame": "Day 0 to 14 after loading dose"
            }, 
            {
                "measure": "PK: Area Under the Concentration Time Curve from time 0 to 14 days (AUC 0-14) of tabalumab after loading dose", 
                "safety_issue": "No", 
                "time_frame": "Day 0 to 14 after loading dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01676701"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of Participants achieving American College of Rheumatology (ACR) Response Rates", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Percentage of Participants achieving European League Against Rheumatism Responder Index based on the 28-joint count (EULAR-28)", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Percentage Change from Baseline to 12 Week Endpoint in American College of Rheumatology (ACR-N)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 Weeks"
            }, 
            {
                "measure": "Change from Baseline to 12 Week Endpoint in ACR Core Set", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 Weeks"
            }, 
            {
                "measure": "Change from Baseline to 12 Week Endpoint in Disease Activity Score based on a 28-joint count and C-reactive protein level (DAS28-CRP)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 Weeks"
            }, 
            {
                "measure": "Number of Operation Failures", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 12 Weeks"
            }, 
            {
                "measure": "Number of Participants Developing Anti-tabalumab Antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to 52 Weeks"
            }, 
            {
                "measure": "Change from Baseline Score in Subcutaneous Administration Assessment Questionnaire (SQAAQ) for the Auto-Injector", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to 8 Weeks"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}